Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Jiqin Zhang, Yongxian Hu, Jiaxuan Yang, et al.
Nature (2022) Vol. 609, Iss. 7926, pp. 369-374
Open Access | Times Cited: 224

Showing 26-50 of 224 citing articles:

Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS–STING pathway
Jing An, Zhang Chuan-ping, Hou-Yuan Qiu, et al.
Nature Biomedical Engineering (2023)
Closed Access | Times Cited: 33
CAR-T Cell Therapy: From the Shop to Cancer Therapy
Ashanti Concepción Uscanga‐Palomeque, Chavez-Escamilla Ana Karina, Cynthia Aracely Alvizo-Báez, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15688-15688
Open Access | Times Cited: 33
Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research
Zhenhua Li, Jun Wang, Jingping Xu, et al.
Military Medical Research (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 30
Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study
Yongxian Hu, Cheng Zu, Mingming Zhang, et al.
EClinicalMedicine (2023) Vol. 60, pp. 102010-102010
Open Access | Times Cited: 30
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Aalia Khan, Sweety Asija, Juber Pendhari, et al.
European Journal Of Haematology (2023) Vol. 112, Iss. 1, pp. 6-18
Open Access | Times Cited: 28
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Jianping Li, Zhiwen Xiao, Donghui Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 27
Modular pooled discovery of synthetic knockin sequences to program durable cell therapies
Franziska Blaeschke, Yan Yi Chen, Ryan Apathy, et al.
Cell (2023) Vol. 186, Iss. 19, pp. 4216-4234.e33
Open Access | Times Cited: 26
Current trends of clinical trials involving CRISPR/Cas systems
Song‐Yang Zhang, Yidi Wang, Dezhi Mao, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 25
Genetically engineered cellular nanoparticles for biomedical applications
Nishta Krishnan, Fei-Xing Peng, Animesh Mohapatra, et al.
Biomaterials (2023) Vol. 296, pp. 122065-122065
Open Access | Times Cited: 23
Metabolic engineering for optimized CAR-T cell therapy
Sarah McPhedran, Gillian Carleton, Julian J. Lum
Nature Metabolism (2024) Vol. 6, Iss. 3, pp. 396-408
Closed Access | Times Cited: 14
CRISPR–Cas9 applications in T cells and adoptive T cell therapies
Xiaoying Chen, Shuhan Zhong, Yonghao Zhan, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 13
Integration of ζ-deficient CARs into the CD3 ζ gene conveys potent cytotoxicity in T and NK cells
Jonas Kath, Clemens Franke, Vanessa Drosdek, et al.
Blood (2024) Vol. 143, Iss. 25, pp. 2599-2611
Open Access | Times Cited: 12
Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies
Yuxian Huang, Yinjie Qin, Yingzhi He, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101082-101082
Open Access | Times Cited: 12
Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
Tao Lei, Yazhuo Wang, Yuchen Zhang, et al.
Leukemia (2024)
Open Access | Times Cited: 11
PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion
Wanyan Ouyang, S Jin, Nan‐Jie Xu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 4, pp. e008429-e008429
Open Access | Times Cited: 10
Reprogramming natural killer cells for cancer therapy
Kexin Wang, Linqin Wang, Yiyun Wang, et al.
Molecular Therapy (2024) Vol. 32, Iss. 9, pp. 2835-2855
Closed Access | Times Cited: 9
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling
Ali Rezvan, Gabrielle Romain, Mohsen Fathi, et al.
Nature Cancer (2024) Vol. 5, Iss. 7, pp. 1010-1023
Closed Access | Times Cited: 9
Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Zhaoyun Liu, Wenhui Lei, Hao Wang, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations
Hyun-Woo Lee, Won‐Yeop Rho, Yoon-Hee Kim, et al.
Molecules (2025) Vol. 30, Iss. 3, pp. 542-542
Open Access | Times Cited: 1
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells
Brandon J. Sytsma, Vincent Allain, Struan Bourke, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Targeted Delivery of mRNA with Polymer–Lipid Nanoparticles for In Vivo Base Editing
Qimingxing Chen, Yan Chang, Xiaoyan He, et al.
ACS Nano (2025)
Closed Access | Times Cited: 1
Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
Chaojie Zhu, Qing Wu, Tao Sheng, et al.
Bioactive Materials (2023) Vol. 33, pp. 377-395
Open Access | Times Cited: 21
Phosphorothioated DNA Engineered Liposomes as a General Platform for Stimuli‐Responsive Cell‐Specific Intracellular Delivery and Genome Editing
Yan An, Xiaohong Chen, Jie He, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 25
Closed Access | Times Cited: 20
Chimeric antigen receptor therapy meets mRNA technology
Jiacai Wu, Weigang Wu, Boping Zhou, et al.
Trends in biotechnology (2023) Vol. 42, Iss. 2, pp. 228-240
Open Access | Times Cited: 20
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Shengkang Huang, Xinyu Wang, Yu Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 19

Scroll to top